Montelukast Orion (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Orion, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of asthma, allergic rhinitis and exercise‑induced bronchoconstriction in both adult and pediatric patients. The medication works by blocking specific inflammatory mediators that cause airway narrowing and nasal congestion, helping to improve breathing and reduce symptom frequency.

GNH USA supplies Montelukast Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage conditions driven by leukotriene‑mediated inflammation.

Asthma: improves control and reduces the frequency of bronchospasm. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate head pain. - Abdominal pain: discomfort in the stomach area. - Cough: occasional dry cough. - Nausea: feeling of queasiness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Mood changes: depression or suicidal thoughts. - Hepatic enzyme elevation: increased liver function test results.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

Pregnancy: category B; use only if benefits outweigh risks. Breastfeeding: monitor infant for possible effects. Renal impairment: assess kidney function; dose may need adjustment. Hepatic impairment: use with caution; monitor liver enzymes. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Montelukast can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast exposure, decreasing efficacy. - Carbamazepine: may lower montelukast levels, compromising therapeutic effect.

Moderate Interactions (Monitor Closely): - Fluconazole: may modestly increase montelukast levels. - Erythromycin: may raise montelukast concentrations. - Warfarin: may require INR monitoring due to potential pharmacodynamic changes.